Back to News

4th January 2018

Manchester medtech firm to begin clinical trials with £1.4m investment


Northern Powerhouse Investment FundNPIF - Maven Equity FinanceGreater Manchester LEP

The North West company behind a medical device that detects life-threatening infections is about to start its first clinical trial after securing a £1.4m investment.

MicroBioSensor, a University of Manchester spin-out, was awarded the seven-figure equity finance in a funding round led by Maven Equity Finance, a Northern Powerhouse Investment Fund (NPIF) product fund managed by Maven Capital Partners, alongside investment from Catapult Ventures.

From its base at the University of Manchester’s innovation centre UMIC, the firm has developed a device the size of an iPad Mini that could help those with kidney failure undergoing peritoneal dialysis.

Dr Gordon Barker, CEO of MicroBioSensor, said: “2018 is going to be a very important year for our 11-strong team as we look to successfully run our first clinical trial which will last through to the second quarter of 2019.

“Essentially, this is all about detecting potentially life-threatening infections early, to improve treatment outcomes.”

According to Dr Barker, of the 50 to 60 thousand Brits on renal replacement therapy, fewer than 10% are on peritoneal dialysis.  One of the reasons that this beneficial treatment isn’t used is that people are worried about potentially life-threatening infection in the peritoneal cavity.

“Our device plugs into the equipment that dialysis patients use every day and detects emerging infections, which means people can stay on peritoneal dialysis for longer which is a good thing.”

Following the trial MicroBioSensor hopes to start selling its device for use in hospitals and clinics, potentially saving money for the NHS as well as improving patient outcomes.

Ken Cooper, Managing Director at British Business Bank, said: “We are delighted that we have been able to make funds available to support MicroBioSensor though this pivotal stage in its development. These clinical trials are a major step towards bringing potentially life-saving medical devices to the UK market.

“We launched the Northern Powerhouse Investment Fund to support businesses with growth aspirations across the North and this is a great example of that.”

MicroBioSensor has also received support through transitional funding and grants, including £983k from Innovate UK; £100k from investor Spark Impact; and £125k from UMIP, a division of the university’s intellectual property commercialisation agent UMI3 Ltd.

The Northern Powerhouse Investment Fund provides microloans, debt and equity investments, ranging from £25,000 to £2m to help a range of small and medium sized businesses to start up, scale up or stay ahead.  The Northern Powerhouse Investment Fund is delivered by The British Business Bank and is supported financially by the European Union using funding from the European Regional Development Fund (ERDF) as part of the European Structural and Investment Funds Growth Programme 2014-2020 and the European Investment Bank.

Photo Caption: Left to right –  Ken Cooper, British Business Bank ,  Gavin Bell, Maven, Nishal Govindji-Bhatt, Microbiosensor and Jake Berry, Northern Powerhouse Minister.

Maven Capital Partners UK LLP is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 495929

Editors Notes


Find Out More

If you would like to meet with one of our appointed Fund Managers to talk in more detail please go to Funds Available to find the Fund Managers operating in your area



£25k – £100k

Learn More
debt finance

Debt Finance

£100k – £750k

Learn More
equity finance

Equity Finance

£50k – £2m

Learn More

Follow npifbbb

For the latest news and views join our mailing list

Join our mailing list

Just add your details below to receive the latest Northern Powerhouse Investment Fund news and information